Results 1 to 10 of about 459,014 (165)

Triple Therapy in Asthma [PDF]

Open Respiratory Archives
Cleofé Fernández Aracil, María del Mar García Ródenas, Luis Manuel Hernández Blasco   +2 more
doaj   +2 more sources

The role of implementation organizations in scaling evidence-based psychosocial interventions

Implementation Science, 2023
Background To bring evidence-based interventions (EBIs) to individuals with behavioral health needs, psychosocial interventions must be delivered at scale.
Margaret E. Crane, Philip C. Kendall, Bruce F. Chorpita, Matthew R. Sanders, Allen R. Miller, Carolyn Webster-Stratton, Jenna McWilliam, Judith S. Beck, Ceth Ashen, Dennis D. Embry, John A. Pickering, Eric L. Daleiden   +11 more
doaj   +1 more source

Results of an open-label, randomized, comparative clinical trial of nifuratel in the eradication of Helicobacter pylori infection in adult patients [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2020
Objective. To assess efficacy and safety of 14-day triple nifuratel-based therapy compared to 14-day standard triple therapy in adult patients with symptomatic H. pylori infection. Materials and Methods.
Dekhnich N.N., Tryapyshko A.A., Trushin I.V., KuzmenkovA.Yu., Kozlov R.S.   +4 more
doaj   +1 more source

Efficacy of Adding Lactoferrin with Triple Therapy for Helicobacter Pylori Eradication in Egyptian Patients [PDF]

International Journal of Medical Arts, 2023
Background: Bovine lactoferrin [BLF] is a glycoprotein with antiviral, antibacterial, and antifungal activities. It is present in mucosal secretions such as saliva, tears, and seminal fluid.
Abdelrhman Elsayed, Mohammed Afify, Yasser Zeitoun, Ahmed Ghazy, Osama Abdelrazek   +4 more
doaj   +1 more source

Cost-effectiveness Analysis Comparing Vonoprazanbased Triple Therapy with Proton Pump Inhibitorbased Therapy in the Treatment of Helicobacter pylori Infection in Thailand

Siriraj Medical Journal, 2021
Objective: Helicobacter pylori (H. pylori) infection is one of the leading causes of gastrointestinal diseases such as dyspepsia, peptic ulcers. Thailand has a 45.9% prevalence of the infection and an increasing rate of resistance to clarithromycin ...
Jadesada Lertsirimunkong, Wiwat Thavornwattanayong, Yosita Napuk, Watcharapong Ajcharoen, Vipavee Chaisitsanguan, Supasuta Wachiranukornkul   +5 more
doaj   +1 more source

Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study

COPD, 2022
Background and objective Triple therapy with an inhaled corticosteroid (ICS), a long-acting β2-agonist bronchodilator (LABA) and a long-acting muscarinic antagonist (LAMA) is recommended as step-up therapy for chronic obstructive pulmonary disease (COPD)
Lili Jiang, Tetyana Kendzerska, Shawn D. Aaron, Therese A. Stukel, Matthew B. Stanbrook, Wan Tan, Priscila Pequeno, Andrea S. Gershon   +7 more
doaj   +1 more source

Efficacy and safety of using probiotics as adjuvants in the eradication of Helicobacter pylori. Systematic review and meta-analysis

Revista de la Facultad de Medicina, 2023
Introduction: Adding probiotics to triple and quadruple therapies has been proposed to improve their effectiveness in the eradication of Helicobacter pylori, but there is controversy about their usefulness.
Gilberto Jaramillo-Trujillo, William Alberto Otero-Regino, Kelly Patricia Estrada-Orozco   +2 more
doaj   +1 more source

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?

Gut and Liver, 2021
Vonoprazan (VPZ), a new potassium-competitive acid blocker, has been approved and used for Helicobacter pylori eradication in Japan. To date, many studies, as well as several systematic reviews and meta-analyses (MAs), have compared VPZ-based 7-day ...
Soichiro Sue, Shin Maeda
doaj   +1 more source

Prescribing Pathways to Triple Therapy: A Multi-Country, Retrospective Observational Study of Adult Patients with Chronic Obstructive Pulmonary Disease

Pulmonary Therapy, 2020
Introduction Maintenance treatment strategies in COPD recommend inhaled corticosteroid (ICS) + long-acting muscarinic antagonist (LAMA) + long-acting β2-agonist (LABA) triple therapy after initial dual therapy.
Jennifer K. Quint, Caroline O’Leary, Alessandra Venerus, Melissa Myland, Ulf Holmgren, Precil Varghese, Hartmut Richter, Geoffray Bizouard, Claudia Cabrera   +8 more
doaj   +1 more source

A prospective randomized trial of FK506-based immunosuppression after renal transplantation [PDF]

, 1995
A group of 204 adult patients was entered into a prospective, randomized trial comparing FK506/pred-nisone with FK506/azathioprine/prednisone after renal transplantation between August 1, 1991 and October 11,1992.
Demetris, AJ, Fung, JJ, Hakala, TR, Irish, W, Jordan, ML, McCauley, J, Mitchell, S, Randhawa, P, Scantlebury, VP, Shapiro, R, Simmons, RL, Starzl, TE, Vivas, C   +12 more
core   +1 more source